Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05485480
Other study ID # 2022-00283; qu20Bandschapp
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 17, 2022
Est. completion date August 2023

Study information

Verified date November 2022
Source University Hospital, Basel, Switzerland
Contact Oliver Bandschapp
Phone +41 61 328 6513
Email oliver.bandschapp@usb.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this double blind, randomised controlled non-inferiority trial is to compare the antinociceptive efficiency of an opioid-sparing and a conventional opioid-based anaesthesia protocol with the help of the CEcertificated Pain Monitoring Device (PMD-200).


Description:

Opioids have been an integral part of general anaesthesia. They are effective in preventing perception of noxious stimuli and ensure intraoperative haemodynamic stability. However, opioids are associated with a number of unwanted side effects (e.g. nausea and vomiting, sedation, ileus, respiratory depression, increased postoperative pain and morphine consumption and hyperalgesia). To minimise these side effects, there has been an interest in developing opioid-sparing anaesthesia protocols. Recently, analgesia nociception monitoring devices have become available. The aim of this double blind, randomised controlled non-inferiority trial is to compare the antinociceptive efficiency of an opioid-sparing and a conventional opioid-based anaesthesia protocol with the help of the CEcertificated Pain Monitoring Device (PMD-200). Patients scheduled to receive general surgical, gynaecological or urological laparoscopic surgery will be randomised into one of the two study groups. Study group A will be anaesthetised with an opioid-sparing protocol and study group B will be anaesthetised with a conventional opioid-based protocol. Intraoperative nociception will be evaluated with PMD-200. Postoperative visits will take place in recovery, 4-5h after surgery and then twice a day. In recovery, the amount of opioids and ketamine needed, pain, postoperative nausea and vomiting (PONV) and the time until the patient is fit for discharge according to the Aldrete score will be assessed. At the 4-5h postoperative visit, the amount of opioids and ketamine needed, maximum pain at rest and at mobilisation, incidence of PONV, mobilisation, micturition and sedation level will be assessed. At the twice daily follow up visits, amount of opioids and other analgesic drugs needed, pain at rest and at mobilisation, gastrointestinal function, quality of night's sleep, incidence of PONV, level of sedation and fitness for discharge home will be assessed. On day one after surgery, the perceived quality of recovery will be assessed with the QoR40 questionnaire.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date August 2023
Est. primary completion date August 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed Consent as documented by signature - Age older than 18 years - Ability to give informed consent - Undergoing scheduled general surgical, gynaecological or urological laparoscopic surgery - American Society of Anesthesiology Score (ASA) status I, II, III Exclusion Criteria: - Inability to give informed consent - ASA status IV and V - Pregnant or breastfeeding women - Allergy to one of the study drugs - Urgent surgery - Surgery with planned regional anaesthesia - Outpatient surgery - Atrioventricular block, intraventricular or sinoatrial block - Atrial fibrillation - Sinus bradycardia - Cardiac insufficiency with a reduced left ventricular ejection fraction of below 40% - Coronary artery disease - Epilepsy - Liver cirrhosis - Chronic kidney disease (Clearance < 50ml/h) - Chronic opioid therapy - Chronic pain

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
conventional opioid-based group
In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
opioid-sparing group
In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil

Locations

Country Name City State
Switzerland Department of Anaesthesiology, University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean of the nociception level as measured by the PMD-200 The PMD-200 device consists of a finger probe which continuously assesses pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature, and finger motion. A value of 0 corresponds to no pain and a value of 100 to maximal pain. A value will be measured every minute from the timepoint of skin incision until skin closure. From the timepoint of skin incision until skin closure (within 1 day)
Secondary Change in Aldrete score Fitness for discharge to ward is checked every 15 minutes with the Aldrete score. The Aldrete score assigned a number of 0, 1, or 2 to 5 variables: activity, respiration, circulation, consciousness, and color. A score of 9 out of 10 is considered adequate for discharge from the recovery. Every 15 minutes in recovery until patient discharge to the ward (within 1 day)
Secondary Amount of morphine needed Amount of morphine needed From the stay in recovery before discharge from the ward (average of 1 week)
Secondary Amount of ketamine needed Amount of ketamine needed From the stay in recovery before discharge from the ward (average of 1 week)
Secondary Change in pain score at rest by numeric rating scale Change in pain score at rest by numeric rating scale (to assess pain severity using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable) From the stay in recovery before discharge from the ward (average of 1 week)
Secondary Change in pain score at movement by numeric rating scale Change in pain score at movement by numeric rating scale (to assess pain severity using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable) From the stay in recovery before discharge from the ward (average of 1 week)
Secondary Quality of night's sleep Quality of night's sleep assessed with a verbal numerical scale from 0 (very poor quality of sleep) to 10 (excellent quality of sleep) From the first postoperative day until discharge from ward (average of 1 week)
Secondary Occurrence of nausea and vomiting Occurrence of postoperative nausea and vomiting (PONV) From the stay in recovery before discharge from the ward (average of 1 week)
Secondary Change in level of sedation Change in level of sedation At 4 hours and then twice daily until discharge from the ward (average of 1 week)
Secondary Perceived quality of recovery by QoR40 questionnaire 40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain At the first postoperative day
Secondary Time to return of gastrointestinal function Time to return of gastrointestinal function as defined as the time from the end of surgery to the first passage of flatus and to the first bowel movement From the stay in recovery before discharge from the ward (average of 1 week)
Secondary Time to return of spontaneous micturition Time to return of spontaneous micturition From the stay in recovery before discharge from the ward (average of 1 week)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A